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ATP analogues and UTP activate phospholipase C (PLC) in bovine
glomerular endothelial cells (gEC). V. Briner and F. Kern, University
HospitalBern, Department of Medicine, Bern, Switzerland. Purine and
pyrimidine nucleotides are produced in blood, vessels and kidney and
may induce both vasoconstriction and vasodilation, thus modulating
glomerular filtration rate (GFR). In glomerular mesangial cells (gMC),
ATP and UTP stimulate phosphoinositol turnover and induce contrac-
tion. The present study investigates the effects of nucleotides on
inositol-1 ,4,5-trisphosphate (1P3) and 1P1 generation and cytosolic free
Ca2 ([Ca2]1) and the receptors involved in signal transduction. The
purine nucleotides ATP, [/3,y-imido]-ATP, ADP and the pyrimidine
UTP induced a dose dependent rise in [Ca2],. A dose of l0 M of these
nucleotides stimulated peak rise in [Ca2] from a basal concentration of
93 2 nmol/liter to 533 23 nmollliter by ATP; to 441 39 nmol/liter
by [p,'-imido]-ATP; to 460 31 nmollliter by ADP; and to 570 44
nmol/liter by UTP. Extracellular Ca2 depletion did not prevent [Ca2]
rise. The nucleotides ATP, [13,y.imido]-ATP, and UTP also stimulated
1P1 formation by 4869 200 cts/well, 2588 199 cts/well, 2707 49
cts/well, respectively. The P2 receptor agonist [csj3-CH2]-ATP did
neither stimulate a [Ca2]1 rise nor desensitize subsequent ATP re-
sponse. The P2 receptor agonist 2-methylthio-ATP (10 M) stimulated
[Ca2]1 rise to peak at 532 43 nmollliter. Adenosine, a P1 receptor
agonist, AMP and CTP had no effect on [Ca2]1 and 1P3 level. ATP and
UTP effects were similar, Maximal effect of either nucleotide could not
be increased by exposure of gEC to ATP and UTP (554 38 nmol/liter).
In summary: In gEC, ATP analogues and UTP may activate PLC
leading to 1P3 generation and rise in [Ca2J. These effects are mediated
by a common nucleotide receptor or distinct purine and pyrimidine
receptors. Since [Ca2] is known to be involved in prostacycline and
EDRF production, these nucleotides therefore may antagonize the
contractile response in gMC and thus, gEC may contribute to the local
regulation of glomerular capillary flow and GFR.
A method for detecting proteinuric factors in patient sera. J. U.
Steiger, M. Hermie, F.P. Brunner, G. Thiel, and H.A. Bock, Abteilung
Nephrologie, Kantonsspital Basel, Switzerland. Sera of nephrotic
patients have been reported to contain a factor which increases albumin
permeability and whose presence is associated with recurrent protein-
uria in kidney grafts. We have established an in vitro detection system
for such factors which is based on the measurement of albumin
permeability in single rabbit glomeruli. Glomeruli without Bowman's
capsule are obtained by fractional sieving and held with a micropipette
during sequential exchanges of superfusion chamber fluid. Glomerular
volume is measured with an image analysis system. After equilibration
in 5% albumin (oncotic pressure = 19.6 mm Hg), the chamber fluid is
replaced by first iso-oncotic and then hypo-oncotic dextran (molecular
wt 250,000). A normal, albumin-impermeable glomerulus will keep its
size when changed to iso-oncotic dextran and will increase with
hypo-oncotic dextran due to "reverse filtration." In contrast, a perme-
able glomerulus will shrink in iso-oncotic dextran, since the inward
oncotic force (albumin) is inferior to the outward force (dextran),
resulting in glomerular water loss. The oncotic pressure of a dextran
solution which creates the same volume as the 5% albumin concentra-
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tion is obtained by interpolation (ir0) and albumin permeability F is
calculated as 1 — 1Ti/1TAJbomjn. Normal rabbit glomeruli were imperme-
able to albumin (1 = 0.04 0.04, N = 10, mean SEM), even when
preindubated with sera of 3 healthy individuals (0.06 0.02, N = 9).
Preincubation with protamin (100 U/mI), which neutralizes anionic
charges of the glomerular basement membrane significantly increased
permeability to 0.58 0.07 (N = 13, P < 0.001). Similar increases in
permeability were found when rabbit glomeruli were incubated with
serum of a patient with membranous glomerulonephritis (recurrent in
two consecutive transplants; 'D = 0.49 0.07, N = 7) and with serum
of a patient with recent onset nephrotic syndrome (t = 0.60 0.05, N
= 5). In conclusion, the present system is capable of detecting pro-
teinuric factors in patient sera. It could serve as a detector system for
identifying the nature of these factors. In addition, it might be useful for
identifying patients which are at risk for recurrent transplant glomeru-
lonephritis.
Mesangial matrix metalloproteinases and their role in glomerulonephri-
tis. H.P. Marti and D.H. Lovett, Department of Medicine, San Fran-
cisco VAMC-University of California at San Francisco, San Francisco,
USA. The integrity of the glomerular extracellular matrix (ECM), which
includes the glomerular basement membrane and the mesangial matrix,
is a prerequisite for normal glomerular structure and function. The key
components of the glomerular ECM are type IV and V collagens,
sulphated proteoglycans, laminin, entactin and fibronectin. Mesangial
cells play an important role in both the synthesis and degradation of the
matrix. ECM proteins are degraded by a group of extracellularly active
proteinases, the matrix metalloproteinases (MMP). These enzymes
belong to the collagenase supergene family, which are secreted in latent
forms and depend on zinc and neutral pH for maximal activity. Due to
the complex composition of the ECM, we have postulated that several
matrix-degrading metalloproteinases must exist, especially within the
centrally located glomerular mesangium. A polymerase chain reaction
(PCR)-based homology cloning strategy was developed to characterize
the spectrum of MMP expressed by cultured human and rat mesangial
cells. Exploiting this method, we defined at the molecular level the
structure of human forms of punctuated metalloproteinase (PUMP-I)
and interstitial coilagenase, along with a rat 72-kDa type IV collage-
nase. After incubation with the inflammatory cytokines interleukin 1
and tumor necrosis factor, a significant increase in the amount of
mRNAs of PUMP-i and 72-kDa type IV collagenase in mesangial cells
was observed. Increased PUMP-l synthesis in vivo was demonstrated
within clinical biopsy specimens of pauci-immune rapidly progressive
glomerulonephritis, in which mesangial hypercellularity was a notice-
able feature. After induction of acute anti-Thy 1.1 nephritis, a model of
immune complex-mediated glomerulonephritis in rats, augmented syn-
thesis of mesangial 72-kDa type IV collagenase was documented. The
probably cytokine-mediated enhanced expression of mesangial MMP
may contribute to the evolution of glomerular destruction in mesangial
cell-mediated forms of glomerulonephritis. Therefore, selective modi-
fication of activity and expression of mesangial MMP may lead to new
kinds of therapy for glomerular inflammatory disease.
LPS modifies the plasminogen activator/plasmin system of the murme
kidney. S. Moll, J.A. Schifferli, J. Huarte, J.D. Vassalli, and A.P.
Sappino, Laboratoire d'Immunonephrologie, Département de Mor-
phologie et Division d'Oncologie, Centre Medical Universitaire, Gen-
eve, Switzerland. Recent observations have shown that urokinase-type
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(u-PA) and tissue-type (t-PA) are produced by distinct epithelial cells in
the murine kidney and released into the urine, suggesting a role for
these enzymes in the maintenance of tubular patency. In order to
determine whether septic shock might modify the renal production of
PAs, we treated adult mice with LPS and analyzed the expression of u-PA,
t-PA and PAl-i mRNAs in the kidney by the combined use of Northern
blots and in situ hybridizations. The enzymatic activity of u-PA and
t-PA was assessed by histological zymography on tissue sections and by
SDS-PAGE zymography of urine. We observed that a single i.p.
injection of 100 g induced a dramatic reduction in u-PA mRNA levels
in proximal and distal tubules. This decrease in mRNA corresponded to
a reduction in u-PA activity in the kidney and in urine. By contrast,
t-PA mRNA levels increased in glomerular cells and in papillary
collecting ducts. This increased content of t-PA mRNA correlated with
an increased expression of activity ifl Situ and in pelvic urine. Finally,
there was a concomitant increase in PAl-i mRNA, which was present
throughout the kidney. In addition, PA-PAl complexes were detected in
the urine of LPS treated animals but not in controls. These results
indicate that a single LPS injection alters the plasmin-catalyzed proteo-
lytic balance in the murine kidney and suggest that a transient decrease
in tubular proteolysis may account for some of the functional alterations
accompanying septic shock.
Assessment of GFR from the k)< body height/P creatinine formula. A.
Bueva and J.-P. Guignard, Service de Pédiatrie, CHUV, Lausanne,
Switzerland. GFR per body surface area being proportional to body
height and inversely proportional to the plasma creatinine (Pcr), a
formula has been proposed to estimate GFR without urine collection:
GFR = k x body height/P. The constant k is usually calculated by
using creatinine clearance (Car) as an estimate of GFR. In order to
evaluate the possible variability of k according to the patient's state of
diuresis, a retrospective analysis of 1768 clearance studies in children
aged 1 to 16 years has been made, and the value of k calculated from
both inulin clearance (C1) and C. Body height and Cr were expressed
in cm and mg/dl, respectively. The results showed that: (a) Cc.
correlates significantly with urine flow rate (y = 87.15 + 6.13x; r =
0.820; P < 0.001); (b) k values calculated from Ccr consequently
increase linearly with urine flow rate (V), values varying from 0.60 at V
below 5 ml/min x 1.73 m2 to 0.84 at V above 15 mI/mm x 1.73 m2; and
(c) the correlation between C1, and k x body height/P, where k had
been calculated from Ccr, showed a substantial scatter of values. A
prospective study in 44 additional children studied in hydropenic
conditions and after water loading confirmed the finding of elevated
values of k during water diuresis (0.72 0.30 SD) as opposed to
hydropenia (0.56 0.10 SD). We conclude that to be useful, the k value
must be calculated from Ci,, and the clearance studies performed in
strictly standardized conditions.
Karyomegalic interstitial nephritis: An HLA-associated disease? M.
Spoendlin, F. Brunner, G. Thiel, and M. Mihatsch, Departments of
internal Medicine and Pathology, University of Base!, Base!, Switzer-
land. Systemic karyomegaly associated with chronic interstitial nephri-
tis was first described in 1978 by Mihatsch reporting on three cases.
Two of them were brothers. Only two other cases with similar renal
biopsy findings are known from the literature. We now report a further
case together with an investigation of his family. Case report: A 35 year
old athletic physical training instructor was referred because of de-
creased renal function. From age 22 to 28 he had been suffering from
recurrent episodes of fever, arthralgia and myalgia of undetermined
origin. Thereafter he had frequent upper respiratory infections and
abscesses of the skin. Slowly deteriorating renal function and mild
proteinuria were first noted at age 26. At referral, there were no
abnormal physical findings, blood pressure 135/65 mm Hg, plasma
creatinine 221 mol/liter, 24-hour creatinine clearance 50 mllmin and
proteinuria 920 mg/24 hours. Urinalysis was unremarkable except for
proteinuria and mild glucosuria. A renal biopsy disclosed interstitial
fibrosis and many tubular cells with large polymorphic nuclei (as
described in the previous cases). The same karyomegalic cells were also
found in urinary cytology. Screening for heavy metal poisoning, viral
infection and immunodeficiency was negative. Family investigation:
Renal function and urinary cytology of the parents, the sister and one of
the sons were normal. The urine of the other 12 years old son showed
karyomegalic cells. His renal function was normal but he had a history
of recurrent infections with chronic otitis media. Our findings support
the association of karyomegaly and interstitial nephritis as an entity. A
genetic predisposition, perhaps linked to the HLA-antigens A9 and
B35, seems likely. All three previous cases as well as the present case
and his karyomegalic son tested positive for HLA A9 and B35. The
common clinical features of the four patients whose renal biopsy was
examined in Basel were male sex, frequent infections, glucosuria and
onset of renal failure during the third decade.
Three years experience with a percutaneously inserted double lumen
catheter for permanent hemodialysis access: A prospective study. P.
Ruedin, C. Laverrière, A. Pechère Bertschi, C. Stoermann Chopard, T.
Etienne, MC. Marti, and M. Leski, Division de Nephrologie et
Département de Chirurgie, Hôpital Cantonal Universitaire, Genève,
Switzerland. Over a three year period, 63 "Perm-cath" catheters (PC),
were inserted percutaneously under local anesthesia into 56 patients
(mean age: 66.5 1.7 years SEM) undergoing maintenance hemodialy-
sis. PC are cuffed dual lumen catheters made of soft silicone rubber.
Sixty PC were placed via the right internal jugular vein and three via the
left internal jugular vein; the catheter tip was positioned into the right
atrium. The procedure was performed with full surgical asepsis and
under vancomycin prophylaxis. PC was placed as first choice vascular
access in 32 patients, most of them suffering from cardiac insufficiency,
ischemic heart disease or peripheral vascular disease. There were five
minor exit-site bleedings and two local hematomas, treated conserva-
tively, following PC insertion. Duration of the PC use ranged from 0.5
to 24.5 months (total duration: 422.5 months). The actuarial PC survival
rate at 1, 3, 6, 12 and 24 months was 98, 92, 87, 83 and 83%,
respectively. Obvious and suspect exit-site infection rates were 0.54
and 1.34 per year of catheter use, respectively. There was no episode of
septicemia. Coumadin was given in 28 patients and aspirin or dipyrida-
mol in seven patients; in 28 cases, patients were free of anticoagulant
treatment. Problems related to inadequate blood flow through the PC
occurred 10.54 times per year of PC use. These episodes were treated
with urokinase (25,000 IU) given into catheter lumen. No clinical
evidence of vein thrombosis was encountered during the study. Seven
PC were removed (spontaneously in 2 cases) because of exit-site
infection (4) or intractable blood flow difficulties (3). This prospective
study shows that percutaneous insertion of the PC is safe. PC provides
a reliable and long-lasting access for hemodialysis, especially when
means of peripheral access are exhausted or if arteriovenous shunt is
contraindicated. The rate of infectious complications is very low and no
case of life-threatening infection occurred. Blood flow difficulties re-
main the principal problem in our experience.
Risk and benefit of oral calcitriol therapy in chronic hemodialysis
patients. D. Kiss, K. Donauer, and K. Gyr, Dialysestation, Medizini-
sche Klinik, Kantonsspital Liestal, Switzerland. To investigate the risk
and benefit of oral calcitriol therapy, we analyzed in 30 chronic
hemodialysis (HD) patients the evolution of the biochemical bone
markers (serum calcium, phosphorus, alkaline phosphatase, i-PTH)
retrospectively. To keep serum phosphorus below 1.8 mmollliter, the
patients were treated either with aluminium hydroxide (group I, N = 12)
or with calcium carbonate (group II, N = 18), and the treatment was
strictly adjusted every month. By this schedule the mean (± SD)
concentration of i-PTH fell significantly lower in group 11(126 48
ng/ml vs. 221 57 ngfml). Serum phosphorus concentration was
comparable in both groups (group 11.78 0.38 mmol/liter and in group
11(1.73 0.33 mmol/liter). In case of insufficient suppression of PTH
activity (i-PTH > 200 ng/ml) the patients were treated with oral
calcitriol (0.25 to 0.5 pg/day) additionally (N = 8 in group I/N = 6 in
group II). In case of increased serum calcium (>2.6 mmol/liter) the
calcium concentration of the dialysate was lowered. Five of the eight
patients of group I and four patients of group 11 developed hypercalce-
mia (serum calcium > 2.8 mmol/liter). In contrast to aluminium
hydroxide calcium containing phosphate binders have a stronger effect
on the suppression of PTH secretion. Oral calcitriol therapy lowers
PTH activity additionally, therefore only in patients with high PTH
activity calcitriol therapy might be used. The lowering of the calcium
concentration of the dialysate may lead to an increase of PTH activity
again, and does not always prevent hypercalcemia. Hyperphos-
phatemia and hyperparathyroidism should be treated with calcium
containing phosphate binders only. Oral calcitriol therapy should only
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be used in patients with insufficiently suppressed PTHactivity, and this
must be done under strict control of the biochemical bone markers.
Calcium acetate or aluminium hydroxide to treat hyperphosphatemia
in maintenance hemodialysis? A prospective randomized cross-over
study. F. Rohner, H.R. Räz, and P. Sandoz, Burgerspital, Solothurn,
Switzerland. Calcium acetate (CaAc) was compared with aluminium
hydroxyde (A1OH) as a phosphate binder in a prospective, randomized
cross-over study including 33 patients on maintainance hemodialysis.
Changes in serum levels of phosphorus, calcium and acid-base ho-
meostasis were evaluated. The data of seven patients were excluded
from analysis for various reasons. While taking AIOH, six of 26 patients
reported gastrointestinal side effects, compared to only one of 26 taking
CaAc. CaAc resulted in a slightly better control of mean serum
phosphate levels (1.75 mmol/liter vs. 1.91 mmol/liter, P = NS) when
ingested in the same daily dose. Mean calcium levels rose from 2.37 to
2.49 mmol/liter (P < 0.01) in patients taking CaAc. Six of 26 patients
developed asymptomatic hypercalcemia (Ca > 2.7 mmol/liter) while
taking CaAc. This was easily controlled by omission of calcitriol and/or
reduction of calcium levels in dialysis fluids from 1.75 mmol/liter to 1.25
mmol/liter in all but one patient. CaAc did not clearly improve uremic
acidosis. Serum potassium levels remained unchanged. Therefore,
CaAc is a well tolerated and effective alternative to AIOH in the control
of hyperphosphatemia. Because of frequent hypercalcemia regular
serum calcium controls are mandatory.
L-carnitine improves vascular refilling in hemodlalysis patients during
ultrafiltration. J. Záruba, W. Probst, A. Knoflach, and U. Binswanger,
Nephrologische Station, Departement Innere Medizin, Universitdtsspi-
tal Zurich, Zurich, Switzerland, The reports on carnitine supplementa-
tion and its benefits in patients undergoing chronic hemodialysis are
controversial. However, recently carnitine was found to reduce the rate
of intra-dialytic hypotensive episodes and muscle cramps. To study the
mechanism involved in this observation, we measured vascular refilling
prior to carnitine supplementation and after four weeks of carnitine
administration (I g i.v. after each dialysis session) in four hemodialysis
patients. The rate constant of vascular refilling (Lp = ml x min x mm
Hg' x 50 kg') was determined from the changes of blood volume and
of colloid-osmotic pressure and normalized for 50 kg lean body mass.
The relative changes of blood volume were monitored continuously by
means of ultrasound velocity, and the changes of colloid-osmotic
pressure were calculated from plasma protein concentrations. At the
beginning of the dialysis session the patients were subjected to an
'ultrafiltration pulse" for 20 minutes. The volume ultraflltrated during
this "pulse" was equivalent to the necessary ultrafiltration-volume per
hour to reach the patients ideal predialysis weight. After four weeks of
carnitine supplementation the serum levels of free carnitine increased
from 36.8 9.7 to 127.5 32.9 (Mean SD, paired t-test, P <0.02). Lp
increased from 3.81 0.58to 7.95 2.82 (Mean SD, P < 0.02, paired
t-test). This corresponds to a mean increase by more than 100%. By
improving the vascular refilling rate carnitine might contribute to better
ultrafiltration tolerance during hemodialysis.
Adequacy of dialysis in high risk patients with end-stage renal disease
on continuous peritoneal dialysis (CAPD). A. Edward and J.A. Cerutti,
Ospedale Civico, Lugano, Switzerland. Adequacy of dialysis has be-
come a crucial factor in patient evaluation in all long-term dialysis
programs. The purpose of this study is to explore the usefulness of urea
kinetic modeling (UKM) and total weekly creatinine clearance (Car) in
relation to the clinical outcome and mortality in a high-risk CAPD
population on conventional therapy (a fixed daily dose of dialysis with
standard solution). The population consisted of 13 females and 17 males
with a mean age of 64 12.42 years with a minimum of 38 and a
maximum of 83 years, a mean time of dialysis of 30 26.6 months with
a minimum of 0.5 and a maximum of 95 months. To define the clinical
outcome, we employed the scoring system of the University of Missouri
and found 70% of the population in the good and intermediate groups
with 30% faffing under the poor grouping. The characteristics of the
three groups are:
Population Total Good Intermediate Poor
Male 17 7 6 4
Female 13 5 5 3
Attributes
Total Ccr 62.4 27.8 82.1 25.9 55.0 12.4 36.5 19.4
liters/
week
Residual 21.9 4.59 40.6 25.3 9.79 14.8 4.45 6.11
Cc
liters/
week
PCR g/kg 0.94 0.23 0.99 0.19 0.94 0.26 0.86 0.23
standard
weight
Albumin 37 0.4 38 3.3 37 3.1 34 6.7
g/liter
Total 2.18 0.83 2.64 0.85 2.14 0.52 1.58 0.48
weekly
Kt/Vurea
Urinary 0.56 0.70 1.00 0.77 0.28 0.44 0.12 0.17
weekly
Kt/Vurea
We arrived at the following conclusions: (1) There is not a strong
correlation between Kt/Vura, PCR, or total weekly creatinine clearance
and the clinical assessment. (2) Kt/Vurea and total weekly creatinine
clearance can be considered a good index for defining the lower limit
below which morbidity and mortality increase. (3) High risk patients
have the same prognosis as normal CAPD patients, provided the
recommended criteria for adequacy are observed: Kt/V0r> 1.5, total
creatinine clearance > 50 liters per week, and a PCR > 0.8 g/kg
standard weight/day. (4) When the recommended criteria for adequate
dialysis are no longer obtainable, an adjustment of the therapy prescrip-
tion must be made.
Adsorption of complement factor D by polyacrylonitrile dialysis mem-
branes. M. Pascual, 0. Plastre, P. Ruedin, and J.A. Schj'ferli, Labo-
ratoire d'Imrnunonephrologie, Division de Nephrologie, Hôpital Can-
tonal de Genéve, Genève, Switzerland. Polyacrylonitrile (PAN)
membrane activates complement poorly, and has been shown to adsorb
C3a, the main anaphylatoxin released during complement activation.
Other studies have indicated that incubation of serum with PAN was
responsible for a loss of complement activity which could not be related
to activation. In the present work we investigated whether factor D, an
essential enzyme of the alternative pathway of complement, might be
adsorbed on PAN. In vitro, there was a loss of hemolytic factor D when
NHS was incubated with PAN dialysis fibers, whereas no loss was
observed with cuprophan (Cu) fibers. In addition, there was a dose and
time dependent binding of purified radiolabeled factor D to PAN, but
not to Cu. Factor D released from PAN by 2 M NaCI restored AP
function in serum immunochemically depleted of factor D (RD). By
contrast, factor D was not functional while adsorbed to PAN fibers. The
eluate from a PAN dialysis filter which had been used for dialysis in a
patient with ESRF contained 38.4 mg of hemolytic factor D, represent-
ing 34% of the proteins eluted, thus indicating that factor D adsorption
was very selective. By immunoblotting, antigenic factor D from the
PAN eluate was shown to be identical to purified human factor D. In six
chronic hemodialysis patients, there was a 81.4% decrease in their
plasma hemolytic factor D after dialysis with PAN. No factor D was
found in the dialysis fluid suggesting that PAN membrane removed
factor D mainly by adsorption. By calculation it was estimated that
dialysis on PAN removed 48 mg of factor D per dialysis session. In five
patients dialyzed with cellulose acetate, there was a 9.6% significant
decrease in hemolytic factor D that could be explained by mass transfer
of the protein to the dialysis fluid. In conclusion, PAN has a selective
capacity to adsorb and remove factor D, a reaction that might contrib-
ute to the diminished capacity of PAN membrane to activate comple-
ment during hemodialysis.
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Impact of dialysis modality on body composition (BC) in patients with
end-stage renal disease (ESRD) as assessed by dual X-ray absorptiometry
(DXA). H. Saxenhofer, F.F. Horber, J.-P. Casez, and Ph. Jaeger,
Medizinische Universitdtspoliklinik, Inselspital, Bern, Switzerland.
Whole body DXA accurately assesses BC in different compartments
such as arms, trunk, legs, and uncovers subtle changes of lean body
mass (LBM), fat mass (FM) and bone mineral content (BMC). Whether
hemodialysis (HD) or continuous ambulatory peritoneal dialysis(CAPD) alters BC differently is unknown. Therefore, using DXA we
investigated 47 HD and 30 CAPD patients as well as 64 healthy controls
(C) matched for age, sex, and body mass index. Compared to C, cortical
(448± l6gvs.524±21;P<0.01)andtrabecular(115l 1285
34; P < 0.02) bone compartments were lower in ESRD patients
irrespective of the dialysis modality applied. Total FM was similar
between the three groups investigated. However, the ratio of upper to
lower FM was higher in female CAPD (1.28 0.10 vs. 0.96 0.08, P
< 0.05) and HD patients (1.10 0.10 vs. 0.83 0.07, P < 0.05),
whereas male dialysis patients demonstrated similar FM distribution to
C. LBM of the trunk and arms were similar in HD and CAPD patients
as compared to C; however, LBM of the legs was lower in male (14.9
0.3 kg vs. 17.1 0.4; P < 0.001) and female (10.2 0.3 kg vs. 11.6
0.2; P < 0.001) HD and CAPD patients. Our data suggest that: (1) both,
cortical and trabecular bone are significantly affected in ESRD inde-
pendent of the dialysis modality used; (2) female but not male patients
have increased central fat stores in the presence of normal total FM;
and (3) both, HD and CAPD are associated with significant muscle
wasting.
Altered body composition in stable renal transplant patients on cyclo.
sporine monotherapy: Impact on lipid and carbohydrate metabolism.
F.F. Horber, R.L. Mathieu, A. Montandon, and Ph. Jaeger, Mediz-
inische Universitatspoliklinik, Inseispital, Berne, Switzerland. Altered
body fat distribution and muscle wasting are classically encountered in
renal transplant patients (RTP), probably as a consequence of immu-
nosuppressive therapy with glucocorticoids. Several months to years
after transplantation, a subgroup of patients can be maintained on a
immunosuppressive monotherapy with cyclosporin A (CsA). Whether
this therapeutic modality is associated with normalization of altered
body fat distribution and muscle mass remains to be determined.
Therefore, 18 RTP, (9 males and 9 females, 64 5 months since
transplantation; CsA-monotherapy: 38 7 months) and 18 age, sex and
body mass index matched healthy volunteers (N) were investigated
using indirect calorimetry (Deltatrac) and dual energy X-ray absorpti-
ometry (Hologic QDR 1000 W). Lean body mass (LBM) was decreased
in patients, mostly due to loss of striated muscle in the legs (14.0 0.7
vs. 16.5 1.0kg, P < 0.01, RTP vs. N). In RTP fat mass was increased
inthehead(l.l3 0.O4vs. 1.01 0.03,P<0.0l)andtrunk(12.6 1.2
vs. 10.2 1.0, P <0.01), but was similar in the extremities as compared
with N. Interestingly, resting energy expenditure (REE) was increased
in RTP by more than 10% as compared with N (32.5 1.0 vs. 29.5 0.6
kcal/kg LBM, P < 0.05). Plasma insulin and glucose concentrations as
well as total serum cholesterol (C) and triglyceride levels and the ratio
of LDL-C to HDL-C all were elevated (P < 0.01) in RTP as compared
with N. In conclusion, RTP on an immunosuppressive monotherapy
with CsA display decreased muscle mass despite discontinuation of
prednisone therapy. The increased upper body fat might, at least in
part, account for peripheral hyperinsulinemia and dyslipidemia ob-
served in RTP even years after successful kidney transplantation.
CsA-induced futile substrate cycling might explain increased REE in
RTP.
Changes in body composition and fuel metabolism early after kidney
transplantation are sex specific and mediated by glucocorticoids. U.
Steiger, J.P. Casez, Ph. Jaeger, A. Montandon, C. Descoeudres, and
F.F. Horber, Policlinic of Medicine, University Hospital, Berne, Swit-
zerland. Kidney transplant patients (KTP) exhibit decreased muscle
mass and increased fat mass. Whether this altered body composition is
due to glucocorticoid therapy or to preexisting renal failure is unclear.
Therefore, 13 KTP and 13 age, sex and body mass index matched
normal healthy volunteers (N) were studied by whole body densitom-
etry (Hologic QDR 1000 W) and indirect calorimetry (Deltatrac). N
were studied only once, while KTP were seen first 45 2 (mean 5EM)
days after kidney transplantation (KT) Idaily dose of prednisone (DDP):
0.29 0.03 mg/kg body wt/day] and again after 152 8 (DDP: 0.24
0.03 mg/kg/day) and 492 6 days (DDP: 0.17 0.02 kg/day). All KTP
were advised to restrict their caloric intake to resting energy expendi-
ture (REE) plus 20% with a protein content of 1.2 g/kg body wt. In KTP
at 42 days after KT, lean mass of the legs was lower by 12.7 3.3% (P
<0.01) than in N, whereas no difference in fat mass and REE could be
detected between KTP and N. In contrast, lipid oxidation (LOX) was
lower (P < 0.01), whereas carbohydrate oxidation (COX) was higher (P
<0.01) than in N. After 150 and 492 days, fat mass increased by 3.9
0.5 and 4.9 0.5 kg respectively in males, but not in females (0.1 0.5
kg). Segmental analysis of the fat compartments revealed an increased
fat mass in all compartments (head, trunk, legs, arms) in males, whereas
in females an increment in fat mass was detected only in the head (P <
0.01). After 492 days lean mass of arms and legs increased by 1.4 0.4
kg (P < 0.05), independent of sex. LOX increased, whereas COX
decreased with decreasing DDP (P < 0.01), being similar between KTP
and N after 492 days of observation. In conclusion, compared with N,
KTP exhibit decreased leg muscle mass which increases slightly during
18 months after KT. KTP exhibit a lipogenic potential (decreased LOX)
due to immunosuppressive therapy with glucocorticoids. Moon face is
the only characteristic feature of fat mass changes induced by exoge-
neous therapy with prednisone in KTP. Reducing DDP to less than 0.1
mg/kg body wt/day allows KTP to normalize fuel metabolism.
Serum hippuric acid concentration in renal allograft rejection and
ureteric obstruction. Andreas Knoflach and Ulrich Binswanger, Neph-
rologische Abteilung, Departement für Innere Medizin, Universi-
tdtsspital, Zurich, Switzerland. Plasma from 35 renal allograft recipi-
ents (21 males and 14 females) was sampled daily and analyzed for
hippuric acid (HA) by HPLC reversed-phase-technique and serum
creatinine. Twelve of these patients showed an acute renal allograft
rejection or a ureter obstruction as proven by clinical signs and biopsy
as well as radiography or ultrasound, respectively. We found a mean
increase of serum hippuric acid in patients with acute rejection by 39.9
.rmol/liter from baseline (range 20.4 to 115.5) three days after initial
increase; this rise was observed already 24 hours before the mean
serum creatinine increased by 107.1 rmol/liter (range 21 to 193). In case
of ureter obstruction HA rose by 1.6 .tmol/liter (range 1 to 8.2),
significantly less than elevations due to rejection. The increase in
creatinine however amounted to 65.3 rmol/liter (range 22 to 140) and
was not different as compared to the change in rejecting patients.
Successful antirejection treatment coincided with a decrease of serum
HA starting. 24 hours earlier than the decrease of the serum creatinine
concentration.
Acute allograft rejection Ureteric obstruction
Creatinine Hippuric acid Creatinine Hippuric acid
p..mol/liter p..mol/liter p..mol/liter pmol/liter
Pat. 1 110—131 n.d—43.0 Pat. 7 80—124 n.d—n.d
Pat. 2 108—267 n.d—26.3 Pat. 8 137—176 n.d—9.2
Pat. 3 79—120 n.d—l1.2 Pat. 9 126—186 n.d—n.d
Pat. 4 324—517 3.8—30.7 Pat. 10 152—237 n.d—n.d
Pat. 5 1023—1069 156.5-272 Pat. 11 99—121 n.d—n.d
Pat. 6 153—336 9.4—29.9 Pat. 12 129—269 5.8—5.8
First measurement: baseline value; second measurement: 3 days after
initial rise. n.d: <3 zmol/liter (detection limit)
Our data suggest that serum hippuric acid, which is excreted by tubular
secretion, could be a sensitive and early marker of acute allograft
rejection. Furthermore, it seems to discriminate between acute renal
allograft rejection and ureteric obstruction.
Azathioprine hypersensitivity mimicking relapses of Goodpasture's
syndrome. M. Stetter, M. Schmidli, and R. Krapf, Medizinische Klinik
B, Kantonsspital, St. Gallen, Switzerland. Side effects due to azathio-
prine (the nitroimidazole derivative of 6-mercaptopurine) can be clas-
sified as toxic (myelosuppression, hepatotoxicity) and idiosyncratic
(that is, fever, rigors, arthralgias, pneumonitis and gastrointestinal
symptoms). While the toxic effects are due to 6-mercaptopurine, the
hypersensitivity reactions are believed to be caused by the nitroimida-
zole moiety. A 21 year old male patient developed terminal renal failure
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due to Goodpasture's syndrome (rapidly progressive glomerulonephri-
tis with linear IgG-deposits, positive circulating anti-basement mem-
brane antibodies, AGBM). He was treated with CAPD and later
hemodialysis and received two renal grafts at age 23 and 27, respec-
tively. He received a total of four courses of azathioprine treatment: 1 x
for Goodpasture's syndrome, and 3 x for rejection episodes. Each
course was followed within four to seven days by high fever, rigors,
arthralgias, diarrhea, myalgias and pulmonary infiltrates with hemop-
toe, which were considered to be consistent clinically with relapses of
Goodpasture's syndrome. However, all signs and symptoms resolved
completely within days upon discontinuation of azathioprine. AGBM
were never elevated and—during one episode—relapse of Goodpas-
ture's could be excluded by open lung biopsy. Treatment of a subse-
quent rejection episode with 6-mercaptopurine was tolerated without
side effects. We conclude that azathioprine hypersensitivity can rnimick
relapse of Goodpasture's syndrome. The hypersensitivity was probably
caused by the nitroimidazole moiety of azathiopnne. Thus, differential
diagnosis of Goodpasture's syndrome (and probably of any "pulmore
nal syndrome") should include azathioprine hypersensitivity.
How living related kidney donors think about their organ donation lto
21 years later. P. Sparta and G. Thiel, Kantonsspita!, Universitat Base!,
Base!, Switzerland. Fifty-six related kidney donors (35 females, 21
males, 17 sisters, 11 brothers, 16 mothers, 11 fathers and one grand-
mother) received a questionnaire with 20 questions written in their own
language (eleven languages), from one up to 21.6 years after donation.
Fifty-one donors completed the questionnaire. Results: (I) Fifty (98%)
were still happy with their former decision to donate a kidney. (2) Eight
(16%) felt they were not informed well enough before donation. (3) Ten
(20%) felt that there was some non-outspoken, slight pressure within
the family in favor of their donation. (4) Twelve (24%) experienced that
the operation itself was worse than expected. (5) Forty-one (80%) were
happy with the hospital care, 2 (4%) were unhappy, and the remaining
were in between. (6). Fifteen (29%) felt esthetically slightly disturbed by
the surgical scar. (7) Thirty-nine (76%) have no or not more back pain
than before donation. (8) Fourteen (27%) had some concrete proposi-
tions as to what could be done better by the involved physicians and
surgeons (7: more attention post-operatively). (9) Thirteen (25%) re-
mained unpaid for a variable postoperative period, as long as they were
unable to work. (10) The duration of income losses varied from nine to
61 days (mainly one month). (11) The following physical complications
occurred related to donation: vein thrombosis on the leg (3), pulmonary
embolism and cardiac arrhythmia (one obese mother), pain/itching!
sensitivity losses around the surgical scar (6), more tire4 (3 patients,
aged 54, 63 and 66 years). (12) Fourteen drugs are currently consumed
that were not taken before donation and could be potentially related to
donation (antihypertensive agents 2; diuretics: 1, NSAID and other
analgesics: 10; antidepressants: 1). (13) Other severe diseases since
donation: stomach cancer in one. (14) Blood pressure was normal
before donation in 48 (94%) and increased in the remaining three. (15)
Blood pressure is believed to be normal still in 31(74%), "too low" in
six (12%) and increased in another seven (14%). (16) The family doctor
found some proteinuria after donation in one and no proteinuria in 26.
The remaining 24 did not know anything about their urine. (17) The
current state of health was felt to be good or fair in 47 (92%). (18) The
personal relation between donor and recipient has improved since
donation in 14 (27%) or remained unchanged in 35 (69%), but got worse
in one. (19) Two donors felt the recipient should express more grati-
tude. (20) The question whether the behavior of close family members
in regard to donation has disappointed the donor was only answered
positively by one. Conclusions: Almost all living related donors remain
in favor of living donation (98%), but the procedure was followed by
some physical, social and psychological problems, which transplant
surgeons and physicians should know about, since the problems can be
solved at least partly.
Evidence for two populations of Na-K-ATPase defined by their ouabain
sensitivity along the rat nephron E. Férail!e, M. Rousselot, and H.
Favre, Division of Nephro!ogy, Hôpita! Cantona! Universilaire, Gen-
eve, Switzerland. By now, three isoforms of the a subunit of the
Na-K-ATPase have been identified. The al isoform exhibits a low
affinity for the specific inhibitor ouabain, whereas the a2 and a3
isoforms have a high affinity for ouabain. In the kidney the presence of
a isoforms other than al is still controversial. This study was designed
to provide evidence for the presence in the rat nephron of different
isoforms by measuring the ouabain sensitivity of the Na-K-ATPase in
single well-identified specific nephron segments. Proximal convoluted
tubule (PCT), medullary thick ascending limb of Henle (MTAL), and
cortical collecting duct (CCD) were obtained by microdissection. The
ouabain sensitivity of the Na-K-ATPase was determined by measuring
the Na-K-ATPase activity in the presence of ouabain concentrations
ranging from 108 M to l0— M. The inhibition curves exhibited a
complex pattern and were fitted using a non-linear regression analysis.
This procedure allowed us to demonstrate, in each segment, the
presence of two populations of Na-K-ATPase characterized by their
ouabain sensitivities. The apparent Ki of the high sensitive population
were l.4 106 M, 8.8 10—6 M, 1.1 106 M, whereas the apparent Ki
of the low sensitive population were 2.6 l0 M, 4.6 1O M,
1.8 i0 M in PCT, MTAL and CCD, respectively. The relative
proportion of these two populations differed from one segment to the
other. High versus low ouabain sensitive population of Na-K-ATPase:
PCT 40 versus 60%, MTAL 20 versus 80%, and CCD 45 versus 55%,
respectively. In conclusion, our results strongly suggest the presence of
at least two different isoforms of the Na-K-ATPase, coexisting in the
same nephron segment.
Rapid stimulation of Na/1I-exchange by 1,25(OH)2 vitamin D3:
Interaction with PTH-dependent inhibition. Ulrich Binswanger, Corinna
Helmie-Koib, Judith Forgo, Branka Mrkic, and Heini Murer, Institut
fur Physiologie, Universitdt Zurich, Switzerland. Opposum kidney(OK) cells were grown to confluency and pH was measured at the
single cell level using BCECF. Apical Na/H- exchange activity was
quantified as rate of Na- dependent pHrecovery from an acid load.
Superfusion with l,25(OH)2 Vit D3 (lOS M) for one minute led to a
stimulation of Na/H-exchange (57 46%, mean SD; P < 0.01,
paired t-test); this effect vanished after five minutes of exposure.
Superfusion with PTH (5 minutes, 10_8 M) led to a decrease in
Na/H-exchange activity (29 15%; P < 0.01); one minute exposure
to l,25(OH)2 Vit D3 during PTH perfusion (5 minutes) led to a
stimulation of NaVH-exchange (36 22%; P < 0.001). Simultaneous
addition of 1,25(OH)2 Vit D3 and PTH also led to a stimulation of
Na/H-exchange activity (30% and 34%; measured after two minutes;N = 2). PTH (but not 1,25(OH)2 Vit D3) was found to increase
intracellular cAMP-content (RIA) and Ca -1evels (Fura-2, cell suspen-
sions). The PTH-dependent increase in Ca-concentration was unaf-
fected by 1 ,25(OH)2 Vit D3. The PTH-dependent accumulation of
cAMP was lowered by the addition of 1 ,25(OH)2 Vit D3 (reduction in
cAMP of about 50%). These data suggest a regulatory control (stimu-
lation) of proximal tubular brush border Na/H-exchange by
I ,25(OH)2 Vit D3. This non-genomic effect might in part be explained by
release from "intrinsic" or hormone-mediated cAMP-dependent inhi-
bition of transport activity.
Potential role of IGF-I in the PTH-related deterioration of renal
function induced by protein diet. J. Caverzasio, T. Shigematsu, andf.P.
Bonjour, Division de Physiopathologie Clinique, Département de Me-
decine, Université de Genéve, Genéve, Switzerland. Recent studies
from this laboratory indicate that parathyroidectomy (PTX) prevents
the progression of kidney damage due to high protein diet in the subtotal
nephrectomized (NX) rat model of chronic renal failure. Associated
with this protection, the difference in the renal compensatory growth
induced by high (HPr) compared to normal (NPr) isocaloric protein diet
was completely abolished by PTX. We recently observed that in this
NX model, before the development of uremia (week 16), the plasma
PTH concentration was slightly but not significantly increased in
sham-NXHPr (31.2 3.7, N = 8) compared to sham-NXNPr rats (22.5
1.1 pg/mI, N = 6) and the blood pressure was not significantly
different between sham-NXHPr, sham-NXNPr and PTX-NXHPr (141.8
7.4, N = 8, 148.3 4.6, N = 6, 153.1 3.9 mm Hg, N = 12,
respectively). To understand the physiological mechanism responsible
for this protection, the changes in either circulating or kidney content of
IGF-I, a growth factor capable of influencing renal compensatory
growth, was analyzed after unilateral nephrectomy (UNX). In UNX
rats, the administration of a HPr diet for five days significantly
increased the kidney weight (KW) (1.28 0.02 g, N = 11) and the
plasma level of IGF-I (365 10 ng/ml) compared to UNX rats fed NPr
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(1.15 0.02g. N = 11, P <0.001 and 306 lOng/mi, N = 11, P <
0.001, respectively). In UNX rats fed HPr, PTX completely abolished
the "compensatory" growth (1.01 0.05 g, N = 7, P < 0.001) and the
increased plasma level of IGF-J (246 14 ng/ml, N = 7, P < 0.001).
There was a highly significant correlation between the change in KW
and plasma level of IGF-I in all three experimental groups (r = 0.685, P
< 0.001). The kidney IGF-I content was not affected either by the
protein diet or PTX. In PTX-NX rats chronically treated with physio-
logical doses of 1 ,25-dihydroxyvitamin D3 which normalized the calce-
mia, the "compensatory" growth and the increased plasma level of
IGF-I induced by HPr were restored towards those in sham-NXHPr
rats. In conclusion, the results of this study strongly suggest that
circulating but not kidney content of IGF-I mediates the PTH and
I ,25-dihydroxyvitamin D3 effects on protein-induced renal compensa-
tory growth and deterioration of kidney function in chronic renal
insufficiency. Whether the circulating level of IGF-I is influenced either
directly by these calciotropic hormones or indirectly by their effects on
the extracellular concentration of calcium remains to be investigated.
Effects of citrate and calcium on Tamm-Horsfall glycoprotein (THP) as
a modifier of calcium oxalate monohydrate (COM) crystal aggregation. B.
Hess, L. Zipperle, and Ph. Jaeger, Medizinische Universitatspoliklinik,
Inseispital, Bern, Switzerland. There has been some controversy about
whether THP—.the most abundant protein in urine from healthy peo-
ple—inhibits or promotes the aggregation of COM crystals (COM-
Aggr). We studied the effects of THP on COM-Aggr in vitro at pH
5.71[NaCI] 200 m in the presence of either 5 m CaCI2 (CA) or 3.5
mM citrate (CIT), or with both 3.5 m citrate and 5 m calcium
(CIT/CA). THPs were individually purified from 24-hour urines of
nine healthy men (N) and seven male idiopathic recurrent calcium stone
formers (RCSF). COM-Aggr in vitro was measured in crystal slurries
(0.7 mg/mI) at 37°C after adding THP to a final concentration of 40
mg/liter. All THPs were dissolved in either CIT or CA or CIT/CA,
and intrinsic viscosities (VISC) were measured using a capillary vis-
cometer at 25°C. All values are mean SEM. In CAP, mean inhibition
of COM-Aggr by all 16 THPs was —2 10%; N-THPs were inhibited by
23 9%, whereas RCSF-THPs did so by —34 11% (P = 0.0013 vs.
N), that is promoted COM-Aggr. VISC was higher in RCSF than in N
(357 52 vs. 138 26 ml/g, P = 0.0012), indicating more polymerized
THP molecules in RCSF. There was a significant negative correlation
between inhibition of COM-Aggr and VISC of THPs (r = 0.866, slope
—0.299, P = 0.0001), that is more polymerized THPs were weaker
inhibitors of COM-Ag8r. In CIT/CA without THP (control condi-
tions), slight promotion of COM-Aggr (—15 2%, P < 0.001 vs. CAP)
occurred; however, all 16 THPs subsequently added were inhibitory (45
5%, P = 0.0001 vs. CAP), and no difference was noted between N
and RCSF. VISC of RCSF-THPs was 214 33 ml/g (P = 0.034 vs.
CAP), not different from N (186 31 mug). In CIT, inhibition by all
THPs increased further to 57 4% (P = 0.007 vs. CIT/CA) without
difference between N and RCSF. VISC of RCSF-THPs again decreased
to 90 40 ml/g (P = 0.015 vs. CIT/CA), indicating least polymerized
THP molecules in the presence of citrate alone. In conclusion, THPs
from RCSF promote COM-Aggr in CAP, whereas N-THPs are mainly
inhibitory. Since inhibition of COM-Aggr by THPs is highest and VISC
lowest in CIT, it is suggested that citrate might play its role as an
"inhibitor" of COM-Aggr, at least in part, by inducing conformational
changes (depolymerization) in THP molecules, thereby turning promo-
tory THPs into inhibitors of COM-Aggr.
Adrenalectomy (ADX) increases phospholipase A2 (PLA2) mRNA,
protein, and enzyme activity. B. Vishwanath, F.J. Frey, M.F. Dailman,
and B.M. Frey, Division of Nephrology, University of Berne, Switzer-
land; Depqrtment of Physiology, UCSF, San Francisco, California,
USA. Clinical evidence suggests that acute withdrawal of chronic
glucocorticoid therapy with suppression of endogenous cortisol produc-
tion in RTX patients is associated with an increased susceptibility to
rejection. Furthermore, experimental and clinical observations re-
vealed an enhanced immunological and inflammatory response in
glucocorticojd deficiency. A key enzyme of the inflammatory response
is the PLA2, which releases arachidonic acid. In order to elucidate
whether glucocorticoid deficiency causes PLA2 up-regulation, the
expression of PLA2 mRNA and protein, as well as the enzyme activity,
were quantified in rats with and without ADX. The mRNA of PLA2 was
quantified by polymerase chain reaction using a constant amount of a
modified PLA2 eDNA transcript as an internal standard. PLA2 message
and activity varied from organ to organ with the lowest values in
kidneys. The PLA2 mRNA was increased by 116 24% in various
tissues of ADX rats. This up-regulation of PLA2 mRNA was ot due to
a nonspecific effect of ADX, since the mRNA levels of other proteins
(c-fos, c-myc, c-erbf3, methallothionein-LI) remained unchanged. The
increase in PLA2 mRNA in ADX rats was reflected by a corresponding
increase in tissue (kidney, lung, spleen, liver) PLA2 enzyme activity
and protein content as assessed by quantitative Western blot analysis.
Thus, ADX increases PLA2 message, protein and activity, an observa-
tion in accordance with the increased susceptibility to inflammatory
reactions in glucocorticoid deficiency.
Role of endogenous endothelin in renal hemodynamics of newborn
rabbits. D. Semama, M. Thonney, f-B. Gouyon, and J.-P. Guignard,
Service de Pédiatrie, CHUV, Lausanne, Switzerland. Endothelin is a
potent vasoconstrictor peptide produced by vascular endothelial cells,
which could play a role in the physiologic regulation of the renal
microcirculation. To test this hypothesis, experiments were performed
in 23 anesthetized and mechanically-ventilated newborn rabbits. Renal
blood flow (RBF) and glomerular filtration rate (GFR) were determined
by the clearance of para-aminohippuric acid and inulin, respectively.
Each animal acted as its own control. In eight newborn rabbits (group
1), a bolus injection of 5 nmol kg' of endothelin caused a marked
increase in mean blood pressure (MBP) and renal vascular resistance
(RVR), leading to a significant fall in GFR (—12 4%) and RBF (—16
3%). A second group of animals (N = 8) was used for testing the in
vivo neutralizing activity of an endothelin-l antiserum. The antiserum
was thereafter infused in seven additional newborn rabbits (group 3), in
order to define the role of endogeneous endothelin in modulating the
function of the immature kidney. The antiserum induced a surprising
increase in RVR (+24 9%,P < 0.05) associated with a fall in GFR
(—17 6%, P < 0.05) and RBF (—18 5%, P < 0.05), while filtration
fraction and MBP remained unchanged. The occurrence of a vasocon-
strictive response to both high-dose endothelin and to its antiserum
could be explained by the recent demonstration that high levels of
endothelin lead to renal vasoconstriction, while lower levels induce
renal vasodilatation. The present results suggest that endogenous
endothelin is active at low levels in normal conditions and that this
peptide plays a role in the physiologic control of renal function but not
MBP.
Effects of endothelin-1 administration on renal function in newborn
rabbits. D. Semama, M. Thonney, J.-B. Gouyon, and J.-P. Guignard,
Service de Pédiatrie, CHUV, Lausanne, Switzerland. Endothelin is a
potent vasoconstrictor. The renal effects of endothelin- 1 were investi-
gated in 16 anesthetized and mechanically-ventilated newborn rabbits.
Renal blood flow (RBF) and glomerular filtration rate (GFR) were
determined by the clearance of para-aminohippuric acid and inulin,
respectively. Each animal acted as its own control. In eight newborn
rabbits, a bolus injection of 5 nmol kg' caused an initial fall in mean
blood pressure (MBP) followed by a gradual but significant increase in
MBP that lasted for 45 minutes. The dramatic increase in renal vascular
resistance (+28 4%), induced by endothelin, led to a fall in GFR (—12
4%) and RBF (—16 3%). In spite of the reduction of GFR and RBF,
urine flow and sodium excretion rates increased significantly (+20 5%
and +49 9%, respectively). The diuretic effect could be ascribed to an
inhibition of AVP-stimulated osmotic water permeability in inner med-
ullary collecting ducts by endothelin. The natriuretic effect has been
ascribed to an inhibition of the inner medullary collecting duct cells
Na/K ATPase. In eight additional newborn rabbits, a bolus injection
of I nmol . kg' of endotheliñ- I—a dose that usually induces marked
renal and systemic vasoconstriction in adult models—did not affect
systemic or renal hemodynamics. In conclusion, endothelin induces
renal and systemic vasoconstriction, and affects water and sodium
homeostasis during the neonatal period. However, these effects occur
under higher doses than those used in adult animals. This age difference
in systemic and renal responsiveness is probably mediated by receptor
immaturity and/or interference of high levels of counteracting hormones
present during the neonatal period.
1 113-hydroxy-steroid dehydrogenase (I1j3OIISD) affects prednisolone/
prednisone ratio in the kidney. M. Conti, G. Delaloye, F.J. Frey, C.
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Marone, and B.M. Frey, Division of Nephrology, University of Berne,
Switzerland, and Department of Medicine, Ospedale S. Giovanni,
Bellinzona, Switzerland. 1 1j3OHSD converts prednisolone (Po) into
biologically inactive prednisone (P). One might predict that tissues with
high activity of 1 1I3OHSD exhibit a low Po/P concentration ratio and
therefore a relatively low immunosuppressive effect and vice versa. In
order to demonstrate the relevance of 1 1OHSD for Po/P ratios, rats
were injected with Po, and Po/P concentrations were measured by
HPLC. The Po/P concentration ratio was about 25 to 50 times higher in
liver than in kidney tissue, and severalfold higher (5- to 15-fold) in lung,
heart, spleen or plasma than in kidney. The tissue distribution of mRNA
of 11 I3OHSD parallels the Po/P ratios. Inhibition of 1 1/3OHSD by
glycyrrhetinic acid (GA) increased the ratio in the kidney tissue three-
to 15-fold. In order to assess the impact of ll/3OHSD on Po/P in
humans, 10 healthy volunteers were given Po as a zero order infusion
for 13 hours with and without GA. Po/P ratios in plasma and urine were
measured. Plasma Po/P was unaffected by GA, however GA increased
the urinary ratio in all subjects. Conclusion: Due to the high activity of
I 1fiOHSD, local conversion of Po to inactive P occurs in the kidney at
a much higher rate than in other tissues. Therefore, the inhibition of the
local enzyme might be a strategy to selectively increase the immuno-
suppressive effect of prednisone therapy in the transplanted kidneys.
The myth of low bone mass in idiopathic calcium renal stone formers.
J.-P. Casez, Gb. Hug, B. Hess, K. Lippuner, D. Ackermann, and Ph.
Jaeger, Policlinique Médicale Universitaire et Clinique Urologique,
Hdpital de L'ile, Berne, Switzerland. To assess bone mineral density
(BMD) in calcium nephrolithiasis, dual energy X-ray absorptiometry
was used at lumbar spine, upper femur (femoral neck, Ward's triangle
and total area), tibial diaphysis, and tibial distal epiphysis. Results
obtained in 99 male idiopathic calcium stone formers were compared
with those of 234 healthy male controls. Patients were investigated on
a free choice diet. Based on the mean of two measurements of 24-hour
urinary excretion rate of calcium, patients were classified as normocal-
ciuric or hypercalciuric calcium stone formers (0. I mmol/kg/day and
>0.1 mmol/kg/day, respectively). The calcium/creatinine concentration
ratio was calculated out of the second (that is, fasting) morning urine.
BMD was compared between calcium stone formers and controls as
well as between hypercalciuric and normocalciuric stone formers using:
(1) non-corrected BMD, (2) BMD corrected for age, height and BMI,
and (3) a skeletal score based on a tercile distribution of BMD values at
the following four sites: lumbar spine, Ward's triangle, tibial diaphysis,
and tibial epiphysis. No significant difference was seen in corrected or
non-corrected BMD at any site, be it in the whole group be it in both
subgroups of stone formers, as compared with the control group. The
skeletal score was significantly lower in calcium stone formers than in
controls (P = 0.04). However, this difference was no longer significant
after exclusion of 5 patients with accepted causes for secondary
osteoporosis. There was a trend for a lower skeletal score in patients
with versus those without history of a low calcium diet in the past, but
no correlation could be found between BMD at any site and current
calcium intake as well as with fasting calcium excretion or with 24-hour
urinary excretion rate of calcium. We conclude that idiopathic calcium
nephrolithiasis is generally not associated with low bone mass, although
calcium restriction might lead to osteopenia in some patients.
Urea elimination during hemodialysis treatment with stable or variable
dialysate sodium. Marcel Auer, Willi Probst, and Ulrich Binswanger,
Nephrologische Abteilung, Department Innere Medizin, Universi-
tdtsspitaj, Zurich, Switzerland. Urea elimination during hemodialysis is
greater at initiation of therapy due to a larger concentration gradient as
compared to the situation at the end of treatment. The rapid decrease of
the serum urea concentration can result in a disequilibrium syndrome.
The present study was undertaken to compare the effect of constant
versus changing sodium content of dialysate on urea extraction by
sampling dialysate every 15 minutes. Six patients were studied each
during a dialysis treatment with a stable dialysate sodium of 140
mmol/liter and with a sodium profile starting at 150 mmol/liter and
reaching continuously 140 mmol/liter after 2.5 hours of treatment. The
blood urea at start of the treatment was 20.9 7.1 mmol/liter with
stable sodium and 19.8 6.6 mmol/liter with sodium profile (difference
not significant). The results of the urea extraction (mmol) were as
follows:
Minutes
0—15 15—30 30—45 45—60
Na stable
Na profile
49.3 19.2
46.8 18.2
51.3 19.0 46.7 19.2
47.8 20.0 45.7 19.5
45.0 17.5
42.1 17.9
Minutes
60—75 75—90 105—120 135—150
Na stable
Na profile
43.5 19.2
38.7 17.5
39.7 15.4 33.5 18.2
36.7 15.0 30.6 13.4
30.2 14.8
27.3 12.0
Differences for each 15 mm. not significant (paired t-test)
The total amount of extracted urea was 408.3 171.6 mmol during
treatment with stable sodium, versus 378.9 159.0 mmol during
treatment with sodium profile (difference not significant). Our data
show a tendency towards lower urea extraction rate and total amount
during treatment with a sodium profile. This might contribute to the
avoidance of a disequilibrium syndrome and to lower dialysis efficiency
under these conditions.
Increase of endotoxin concentration due to bacterial contamination of
the dialysate during dialysis. D. Kiss, K. Donauer, and K. Gyr,
Dialysestation, Medizinische Klinik, Kantonsspital Liestal, Switzer-
land. The endotoxin concentration and the bacterial contamination of
purified water and dialysate at the start and at the end of treatment were
investigated. As a buffer acetate or bicarbonate was used. The endo-
toxin concentration was determined by a quantitative colorimetric
assay. The bacterial contamination was determined in spot samples, by
placing bacterial filters in the water and the dialysate pathway, respec-
tively. The endotoxin concentration of treated water was 12.2 4.5
pg/mi (N = 26). In the dialysate the endotoxin concentration was 25.8
20.6 pg/mI at the start of the treatment. At the end of treatment the
endotoxin concentration increased significantly to 52.6 43.5 pg/ml.
The increase of endotoxin concentration was significantly higher during
bicarbonate dialysis (+35% vs. +67%). The bacterial contamination
was positive in all samples performed. In spite of regular disinfection of
the dialysis machine, there was a significant increase of endotoxin
concentration during dialysis. During bicarbonate dialysis the increase
of endotoxin concentration is significantly higher than during acetate
dialysis. Bacterial growth within the dialysis machine might contribute
to this phenomenon.
Peritonitis due to perforation of the distal ileum by a rosemary branch
in a patient on continuous ambulatory peritoneal dialysis (CAPD). A.
Edward, E. Battaglia, E. Walder, and J.A. Cerutti, Reparto di Nefro-
logia, Ospedale Civico, Lugano, Switzerland. A 63 year old, male,
insulin dependent diabetic who has been treated for end-stage renal
disease by CAPD for 40 months was admitted to our unit with cloudy
dialysate but few other symptoms. The following comorbid conditions
existed at the time of initiation of dialysis: severe progressive retinop-
athy, hypertension, peripheral neuropathy, gastroparesis, peripheral
vascular disease, and ischemic heart disease. He complained of nausea
and vomiting, had slight abdominal pain, and a temperature of 37.2°C.
Acute peritonitis due to both gram-positive and gram-negative organ-
isms was diagnosed and the appropriate antibiotic therapy was initiated.
During the next few days the dialysate remalned cloudy and the
abdominal pain was localized to the right lower abdominal quadrant and
became aggravated. Sonography, X-ray and barium enema examina-
tions revealed normal findings. A laparoscopy was then performed
revealing a fibrous layer with a thin foreign body protruding at the
terminal ileum. This foreign body was then removed, and since there
was no intestinal leakage, no suture was employed. This foreign body
was identified as a rosemary stick 5.5 cm long. After the removal of the
foreign body we were able to continue CAPD without interruption. All
symptoms abated, dialysate remained clear with negative microbiology.
Incidence of pneumocystis carini pneumonia (PCP) after kidney allo-
transplantation (KA): When is prophylactic treatment needed? Ann-
Kathrin Schwarzkopf, Ruedi Speich, Gerald Keusch, and Ulrich
Binswanger, Nephrologische Abteilung, Departement fur innere
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Medizin, Universitatsspital Zurich, Switzerland. An increasing rate of
PCP after KA was observed starting in 1989. Until 1991, nine cases out
of 205 allotransplantations were diagnosed. 80/205 patients (group I)
received induction immunosuppression with ATG, prednisone (P) and
azathioprine (A); ATG was switched to cyclosporin A (CsA) after seven
to 10 days. 126/205 (group II) received triple immunosuppression with
P, A, CsA immediately after kidney grafting. PCP occurred 36 to 117
days after transplantation in 7/80 and 2/126 patients, respectively(-test: P < 0.05). PCP disease related to rejection therapy with
ongoing triple immunosuppression is outlined in the table. (Number of
patients lost).
Rejection therapy
PcP
N group I group II N
no rejection
P-pulses
P+ATG
P+OKT
P+ATG+OKT
26
37
I
16
—
1
2
—
4(2)
—
—
1(1)
—
—
1(1)
49
40
24
4
8
P-pulses with and without induction therapy are associated with a low
rate of PCP. Expanding the number of antirejection agents results in
4/17 and 1/36 incidences of PCP for group I and II, respectively (, P
= NS). P-pulses followed by OKT3 treatment (plus ATG in one case)
were associated with 5/28 PCP as opposed to 3/77 after P-pulses alone(, P < 0.06) and no disease after P + ATG. Three-fourths of the fatal
cases occurred in patients with multiple infections, PCP being a
contributing factor to the main cause of death. In conclusion, P-pulses
followed by OKT3 rejection treatment include a risk for PCP, which
might be reduced by prophylactic therapy.
Antilymphocytic globulins may promote the development of monoclo-
nal gammopathy after renal transplantation. J. Passweg, H.A. Bock,
and G. Thiel. Abteilung Nephrologie, Kantonsspital Basel, Basel,
Switzerland. We retrospectively studied the incidence of monoclonal
gammopathy in 436 renal transplant patients from this center trans-
planted between 1982 and 1991. Immunoelectrophoresis was performed
at yearly intervals after transplantation in 318 of the 436 patients. There
were 24 cases of clonal gammopathy: 18 were monoclonal, six were bi-,
or triclonal. As in other gammopathy patients, there was a predomi-
nance of IgG and K-light chain subtypes (IgG: 21, IgA: 1,1gM: 2, : 17,
A: 11). Gammopathy was transient in five patients. The five-year
cumulative incidence of gammopathy was 8% by life-table analysis,
much higher than in the same age group of the general population. None
of the patients developed multiple myeloma during follow-up (median
2.5 years; range 0—9). Twenty-one are currently alive and well, and
three died of unrelated causes. In one patient, gammopathy coincided
with a non-Hodgkin's Lymphoma which was successfully treated by
chemotherapy. The median age of patients with gammopathy was 52
(16—62) years at transplantation and was similar to patients without
gammopathy [49 (9—71) years]. Eighteen of the 24 gammopathies
appeared within the first two years after transplantation. The use of
antilymphocytic antibodies in the initial immunosuppressive regimen
conveyed a significantly increased risk of developing monoclonal gam-
mopathy: 11 of 15 patients who developed gammopathy within the first
two years after transplantation had received OKT3 or ATG, whereas
only 81 of 235 first cadaveric transplants during the same time period
had received this therapy (P < 0.0005). This may explain, why in
1989—1990, when antilymphocytic antibodies were more often used, we
observed a remarkable increase (P <0.005) of the two-year incidence of
gammopathy (9/74), when compared to the years 1982—1988 (7/236). In
conclusion, monoclonal gammopathy is an infrequent complication of
renal transplantation. Immunosuppressive induction therapy with anti-
lymphocytic substances may promote its development. Further fol-
low-up of these patients is warranted to evaluate the dignity of this
syndrome.
Prophylactic oral anticoagulation in nephrotic patients: A decision
analysis. F.P. Sarasin, and J.A. Schifferli, Division of Nephrology,
University of Geneva Medical School, Geneva, Switzerland. Thrombo-
embolic episodes, including deep vein thrombosis in the legs (DVT),
and renal vein thrombosis (RVT), remain one of the most serious
complications of nephrotic syndrome. Once the diagnosis of acute
thrombosis is established, oral anticoagulation therapy should be
started immediately, but whether the high incidence of thromboembolic
events justifies its prophylactic administration remains controversial.
Using a Markov decision analysis model, explicitly considering the
consequences of recurrent embolic and bleeding events, we compared
a strategy of oral anticoagulant therapy (AC) started immediately after
a first thromboembolic episode with a strategy of prophylactic oral
anticoagulant therapy (ProphAC). From the literature, we estimated the
rate of RVT to be 9%/year and of DVT to be 3%/year, and calculated
the life expectancy (LE) and the number of fatal complications from
embolic and major bleeding events for a hypothetical cohort of 10,000
fifty-year old patients with membranous glomerulopathy. If they re-
mained nephrotic for two years, the analysis revealed:
Strategy LE (years) Fatal emboli Fatal bleeding
AC 16.3 271 13
ProphAC 16.6 47 69
Excluding patients with diabetic nephropathy, the overall number of
fatal emboli prevented by the ProphAC strategy exceeded the one of
fatal bleeding events for all clinically meaningful ranges of the following
parameters: age, nephrotic syndrome duration, DVT and RVT rates,
likelihood of embolization, and mortality rates of embolic and bleeding
events. We conclude that in the clinical setting of nephrotic syndrome,
the benefits provided by prophylactic oral anticoagulation outweigh its
risks because of the extremely high rate of thromboembolic episodes.
Use of sandimmune (SIM) in idiopathic nephrotic syndrome. B. von
Graffenried, Klinische Forschung, Sandoz Pharma AG, Base!, Switzer-
land. Three hundred forty-one patients were treated with SIM with the
aim of inducing remission. One hundred forty-six had minimal change
nephropathy (MCN), and 195 had focal segmental glomerulosclerosis
(FSGS); 104 were steroid-dependent (SD, 82 were MCN) and 226 were
steroid-resistant (SR, 163 were FSGS); steroid status was unknown for
11. Mean SIM doses were 4.7 mg/kg/day in the 213 adults and 6.0
mg/kg/d in the 128 children. In SD patients, complete remissions (CR)
were achieved in 80%, and partial remissions (PR) in 10%. In SR
patients treated with SIM alone, CR occurred in 14% and PR in 25%,
significantly more than in untreated controls. In SR patients treated
with SIM + low dose prednisone, responder rates were higher (CR
25%, PR 33%). Median time until remission was one month in MCN and
two months in FSGS. There was no correlation between SIM blood
trough levels and efficacy. Complete remission was maintained for six
months in 76% if SIM was continued, but in only 20% six months after
stopping therapy. In a further 134 SD patients SIM was used to maintain
steroid-induced remissions. This was possible in 87% despite with-
drawal of steroids. In two randomized studies, SIM was as effective as
chiorambucil and cyclophosphamide, but relapses occurred faster after
withdrawal of SIM. Catch-up growth was observed in children upon
steroid withdrawal. SIM was discontinued because of adverse events in
7.6%, mostly because of renal dysfunction. In most cases, these
patients already had abnormal renal function at baseline and were
treatment failures. In renal biopsies, moderate interstitial fibrosis with-
out arteriolopathy was seen in 3/34 patients with MCN. In 2/12 patients
with FSGS, SIM-nephropathy was suspected. The most frequent ad-
verse events were hypertrichosis, gingival hyperplasia, gastrointestinal
complaints, and hypertension. SIM can be recommended in steroid-
resistant NS and in steroid-dependent forms failing on cytostatic
agents.
Effects of calcium salts and different calcium (Ca) dialysate concentra-
tions on the mineral metabolism of hemodialysis (lID) patients. C.
Zehnder, M. Kränzlin, and R. Kizhakekkara, Division of Nephrology,
Kantonsspital, Aarau, Switzerland. Ca salts for the control of hyper-
phosphatemia in dialysis patients are now widely used; unfortunately,
they may cause hypercalcemia. To avoid this complication, dialysates
(D) with reduced Ca concentrations are increasingly recommended. In
this prospective study we analyzed the effect of Ca salts and different
Ca D concentrations on the mineral metabolism of 12 HD patients. The
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study was divided into four three month periods according to the D Ca:
I standard 1.75; 111.25; III 1.5; IV 1.75 mmol/liter, Ca salts [11 patients
Ca acetate (Ca ac), 1 patient Ca ketoglutarate] were adjusted in order to
achieve normal serum phosphate (sPO4) concentrations. At baseline
and at the end of each period serum Ca (sCa), sPO4, alkaline phos-
phatase (aP), intact parathormone (iPTH), osteocalcin (OC) and 1,25
dihydroxy vitamin D3 (l,25(OH)2D3) were measured. At baseline three
patients had high iPTH (320.8 nglml) and were analyzed separately.
Three patients were transplanted after seven months, Results were as
follows (means):
Ca dose
mmol/
day
sCa
mmol
Iliter
sPO4
mmol/
liter
aP
JUt iPTH
liter ng/ml
OC
ng/ml
1,25(OH)2D3
pmol/liter
baseline
I Ca 1.75
II Ca 1.25
III Ca 1.50
IV Ca 1.75
23.3
21.7
25.0
25.4
22.5
2.61
2.62
2.38a
2.46
2.71
2.06
1.96
239b
2.08
1.78
117.4 30.0
98.4 22.4
120.2 613b
88.7 38.3
89.8 29.5
16.4
17.8
23.2
19.5
18.7
18.5
15.8
11.2
9.7
11.3
a P < o.oo, bp < 0.01
3/9 patients became hypercalcemic in I and 3/6 in IV. 4/9 patients
developed elevated concentrations of iPTH with D Ca 1.25 mmol/liter.
l,25(OH)2D3 was generally very low. In the three patients with hyper-
parathyreoidism iPTH remained unchanged (398.6, 435.9, 354.0 and
399.0 ng/ml in I through IV). Conclusions: In our HD patients with
normal iVFH, the reduction of Ca D to 1.25 mmol/liter led to lower sCa
concentrations with compensatory hyperphosphatemia and to stimula-
tion of PTH secretion (and possibly increasing bone turnover with rising
trend of OC) in spite of a daily Ca dose of 25 mmol (4 g) Ca ac. Lowering
of D Ca should be done with caution.
Effect of combined pancreas-kidney transplantation on fasting and
postprandial lipid levels. H. Drexel, J.A. Bleisch, G. Kuster, J, Záruba,
F.W. Amann, and U. Binswanger, Departement Innere Medizin, Uni-
versitatsspital Zurich, Switzerland. Although fasting lipid levels of
patients with insulin-dependent diabetes mellitus (IDDM) improve after
combined pancreas-kidney transplantation, the incidence of atheroscle-
rotic complications in these patients remains increased. In search for
other possible atherogenic factors, parameters of postprandial lipid
transport were studied in eight IDDM patients with a kidney graft (KD)
and seven with a combined pancreas-kidney graft (PK), and compared
to those of eight non-diabetic kidney graft recipients (controls, K). Six
hours after a standardized vitamin A-enriched fatty meal, postprandial
plasma levels of chylomicrons and chylomicron remnants were quanti-
tated by measuring retinyl palmitate concentrations in density fractions
>1.006 and <1.006 g/mI. Also, fasting and postprandial plasma levels of
triglycerides, cholesterol, HDL cholesterol, HDL2 cholesterol, HDL3
cholesterol, apolipoproteins A-I and B, insulin and C-peptide were
measured by routine methods. Postprandial chylomicron remnant-
associated retinyl palmitate was significantly elevated in the PK group
as compared to the KD and K groups (mean SD 2796 1037 vs. 1221
610 ng/ml, P = 0.0038; and 2796 1037 vs. 1500 721 ng/ml, P =
0.0151), respectively. In comparison with group K, group PK had lower
fasting and postprandial levels of triglycerides (1.04 0.27 vs. 2.11
0.74 mmollliter at 0 hours, P = 0.0078; and 1.56 0.44 vs. 2.89 1.35
mmol/liter at 6 hours, P = 0.0206), and Apo B (0.98 0.16 vs. 1.54
0.61 g/l at 0 hours, P = 0.0055; and 1.01 0.19 vs. 1.56 0.59g/liter
at 6 hours, P = 0.0151). We conclude that IDDM patients with a
functioning pancreas graft exhibit an important defect of postprandial
chylomicron remnant clearance. Because remnant particles are athero-
genic, this defect may predispose pancreas graft recipients to athero-
sclerotic complications in spite of their favorable fasting lipid profile.
Immunoprophylaxis against CMV in seronegative recipients of kidney
allografts from seropositive donors. Stefan Mariacher, Ruedi Speich,
Gerald Keusch, John D. Auracher, Werner Wunderli, Reinhard Zbin-
den, Felix Largiadêr, and Lunch Binswanger, Universitatsspital Zür-
ich, Switzerland. High risk patients were analyzed during a period with
immunoprophylaxis (Cytotect, 4 mg/kg body wt; day 0, 2, 4, 14, 28)
from 1.1.89 to 31.10.91 and compared to patients without this treatment
observed from 1.1.84 to 31.12.88. Results were as follows:
Serological and disease state
with IP
N = 12
without IPN 26
Seroconversion 8/12 19/26
asymptomatic 2/8 2/19
CMV disease 6/8 17/19
moderate 4/6 11/17
severe 2/6 6/17
death 0/8 3/19
Clinical signs
fever 5/6 16/17
leukopenia 2/6 14/17
thrombopenia 2/6 6/17
hepatitis — 13/17
pneumonitis 2/6 6/17
pericarditis — 2/17
myocarditis — 1/17
encephalitis — 5/17
renal failure — 5/17
Frequency of seroconversion and disease was not altered by immuno-
prophylaxis; however, severity of disease and number of organs in-
volved are aggravated and higher without prophylactic treatment.
A randomized prospective trial of prophylactic unmunosuppression
with OKT3 versus ATG-Fresenius (ATG-F) after renal transplantation.
H.A. Bock, R. Zürcher, M. Mihatsch, J. Landmann, and G. Thiel,
Abteilung Nephrologie und Organtranspiantation, Kantonsspital
Basel, Base!, Switzerland. We carried out a randomized prospective
trial in 104 consecutive renal transplant recipients to compare prophy-
lactic administration of monoclonal OKT3 (5 mg/day for 7 days from
day 0) with polyclonal rabbit ATG-F (4 mg/kg/d for 7 days from day 0).
Concomitant immunosuppression included azathioprin and steroids
from day 0 and cyclosporin A from day 4. Target parameters were
one-year graft and patient survival, rejection and infection rates and
graft function. The present data include six-month follow-up in all
patients and one-year follow-up in 73%. The study groups (N = 52 each)
were well matched for all relevant parameters. Four patients in the
OKT3 group and one patient in the ATG-F group died, all due to severe
infection. Seven additional grafts in the OKT3 group and three in the
ATG-F group were lost, mainly (6 and 2, respectively) due to vascular
rejection. No lymphomas were observed.
OKT3 ATG-F P
1-yr survival Patient 92% 98% NS
(Kaplan-Meier) Graft 78% 92% <0.05
Rejections/patient "Clinical" 1.00 0.16 0.75 0.14 NS
Mean SEM Biopsy-
proven
0.52 0.10 0.31 0.09 NS
Infections/patient Severe 0.90 0.22 0.63 0.15 NS
Mean SEM Minor 2.19 0.24 1.33 0.16 <0.05
I-yr creatinine mol/1iter 137 9 139 15 NS
Side effects T> 37.5°C 41/52 8/52 <0.001
1st week
Other: 23/52 5/52 <0.001
headache,
dyspnea,
pulm.
edema, 01
tract
The high incidence of side effects in the OKT3 group occurred despite
prophylactic steroids (1 g MP i.v. one to four hours before OKT3 or
ATG-F). OKT3 patients were less likely to survive the first year without
biopsy-proven rejection (58% vs. 76%, P < 0.05). In conclusion,
prophylactic administration of OKT3 does not improve outcome or
diminish immunological graft loss when compared to ATG-F, but
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conveys an increased rate of infections and side effects. For prophy-
lactic immunosuppression after renal transplantation, ATG-F appears
to be preferable over OKT3.
Excellent uricosuric efficacy of benzbromarone in cyclosporin A treated
renal transplant patients: A prospective study. R.M. Zürcher, H.A.
Bock, and G. Thiel, Abteilung für Nephrologie, Kantonsspital Base!,
Basel, Switzerland. Patients on cyclosporin A (CsA) often develop
hyperuricemia and gout. Since allopurinol may be undesirable because
of its interaction with azathioprine, we prospectively studied the
uricosuric efficacy of benzbromarone (Bbr; Desurica) in hyperuricemic
patients on CsA. Seventeen CsA-treated renal transplant patients with
stable graft function and hyperuricemia (>359 mol/liter for females,
>491 smolIliter for males) were given 100 mg of benzbromarone daily
for four weeks in addition to their established medication.
before Bbr 1 week Bbr 4 weeks Bbr
Creatinine clearance 48.6 4.6 44.1 3.8
mI/mm
Plasma uric acid pnolf 1 570 22 296 26" 320 28b
Fractional uric acid 5.8 0.5 16.6
clearance %
Urinary uric acid excretion 2212 231 3077 293k
pnol/24 hr
Data are given as mean SEM; aP < 0.01; b P < 0.001
Benzbromarone normalized plasma uric acid in 15 of 17 patients. The
remaining two patients had creatinine clearances of 23 and 25 mI/mm,
the lowest of the entire study group. The relative increase of fractional
uric acid clearance closely correlated with baseline creatinine clearance
(r = 0.64, P < 0.005). None of the patients experienced any side effects.
There were no changes in electrolytes, liver enzymes or hematologic
parameters. In conclusion, benzbromarone normalized serum uric acid
in all CsA-treated renal transplant recipients with creatinine clearance
>25 ml/min. The increase in renal uric acid excretion probably reflects
diminished extrarenal uric acid elimination, which is expected to occur
as plasma uric acid is normalized. Due to its lack of significant side
effects, benzbromarone appears to be preferable to allopurinol in CsA
treated renal transplant recipients with a creatinine clearance above 25
mllmin.
Post-transplant renal bone disease. V. Briner, G. Thiel, M.C. Faugere,
B. Bognar, J. Landmann, V. Kamber, and H. Malluche, Division of
Nephrology, Base!, Switzerland and Lexington, Kentucky, USA. After
renal transplantation (RT) and restoration of glomerular filtration and
production of l,25(OH)2D3, renal osteodystrophy (OD) is expected to
resolve. However, patients receiving azathioprine (AZA) and pred-
nisone (P) develop osteopenia. The present study prospectively inves-
tigates serum parameters of bone metabolism and histologic changes of
bone in patients on cyclosporin A (CsA) with low or no maintenance P
dose over a two year period. After RT in 34 patients (age: 18 to 67 years)
immunosuppressive therapy (1ST) was initiated with CsA (5 mg/kg body
wt), AZA (2 mg/kg) and P (0.5 mg/kg). AZA was discontinued after two
months and P tapered. To suppress rejection 18 patients required
maintenance P therapy. After RT high PTH and osteocalcin (Gla)
decreased while 1 ,25(OH)2D3 increased significantly. Alkaline phos-
phatase increased transiently after RT. At RT bone histology revealed
mixed uremic OD in 63%, adynamic bone disease in 33.5%, low
turnover osteomalacia in 4% of patients. There was a positive relation-
ship between PTH and Gla and histologic parameters of bone formation
and resorption (P < 0.01). In 85.4% of biopsies there was aluminum
staining which decreased after RT. Patients with initial biopsy of mixed
OD tended to decrease while patients with initial biopsies with ady-
namic OD tended to increase bone turnover within one year after RT.
Bone volume did not change after RT. Conclusion: With the present
regimen of 1ST pre-existing renal OD improves after successful RT
without loss of bone volume.
Outcome after renal transplantation of patients with diabetic nephrop.
athy and of patients older than 60 years of age. A. Fischer, and M. Leski,
Département de Médecine, Hôpital Cantonal Universitaire de Genève,
Genève, Switzerland. We reviewed the experience of a small transplan-
tation center (20 to 30 renal transplantations a year) for patients
considered at increased risk for this procedure. Between September
1983 (introduction of cyclosporine) and April 1992, 198 kidney allografts
(almost exclusively from cadaveric donors) were performed, of which
163 were followed at our institution. We retrospectively compared the
outcome of the allografts transplanted into patients with diabetic
nephropathy (N = 23), and into patients older than age 60 (N = 26),
with those transplanted into patients with neither risk factor (N = 114).
One and three years graft survivals were, respectively: 83% and 78%;
92% and 82%; 87% and 79%. One and three years patient survivals were
respectively: 90% and 90%; 96% and 91%; 97% and 97%. Morbidity, as
assessed by the number of days spent in the hospital after the proce-
dure, was increased for the diabetic population. Patients older than 60
years of age developed less rejection episodes in the first three months
after transplantation. Our results favorably compare with those of
larger series in the literature. Although this study lacks statistical power
because of the small number of cases, it interestingly shows no
difference in outcome between the groups at increased risk and the
group without these risk factors. This may partly be explained by a low
incidence of cardiovascular complications in the patients considered at
increased risk, due to a careful selection.
